Filing Flows › Cytek Biosciences (CTKB) › Guidance & outlook
Cytek Biosciences (CTKB) guidance and outlook
Cytek Biosciences (CTKB) narrowed its guidance on Nov 4, 2026: Revenue $208M–$211M for FY2026. Cytek Biosciences' 10-Q filed Nov 4, 2026 makes 22 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $208M–$211M | reaffirmed |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- We intend to continue to make significant investments in research and development in the future.
- We expect to continue to invest in our commercial infrastructure through hiring additional employees with strong scientific and technical backgrounds to support growth in our instrument sales as well as our planned expansion of reagents offerings and panel design capabilities.
- We also plan to continue to invest in sales, marketing and business development across the globe to drive commercialization of our products.
- We expect our expenses will increase substantially in connection with our ongoing activities, as we:
- We believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by multiple factors as described below, each of which presents growth opportunities for our business.
- We plan to drive global customer adoption through business development efforts, direct sales and marketing and third-party distributions.
- We intend to continue increasing our workforce to support our growth.
- We believe our expanding installed base of instruments to new and existing customers will provide us with greater leverage to drive pull-through for reagent and service revenue, which are recurring by nature.
- Furthermore, as we develop and identify new applications and products, we expect to further increase pull-through across our installed base.
- We expect recurring revenue on an absolute basis to increase and become an increasingly important contributor to our revenue as our installed base expands.
- Although we expect sales of our instruments to continue to represent the largest percentage of our revenue in the future, we expect service revenue to increase as a percentage of our total revenue and our gross margins to experience a corresponding improvement as we grow our installed base and increase our focus on leveraging our fixed manufacturing and service overhead costs.
- In the near term, we expect the continued leveraging of fixed manufacturing and service overhead costs, optimization of our manufacturing processes, and material cost fluctuations to have the greatest impact on our gross margin.
Cytek Biosciences' latest quarter
Cytek Biosciences, Q3 2026: revenue $53.2M (+2% year over year), operating margin -15.8%, net loss $6.1M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
Questions
Did Cytek Biosciences raise or lower its guidance?
Cytek Biosciences (CTKB) narrowed its guidance on Nov 4, 2026: Revenue $208M–$211M for FY2026.
What does Cytek Biosciences expect?
We intend to continue to make significant investments in research and development in the future. We expect to continue to invest in our commercial infrastructure through hiring additional employees with strong scientific and technical backgrounds to support growth in our instrument sales as well as our planned expansion of reagents offerings and panel design capabilities. We also plan to continue to invest in sales, marketing and business development across the globe to drive commercialization of our products.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.